Footnotes (127)



Regulating Risks in Pharmaceutical Law: The Need of an Optimal Interplay Between Products Safety and Products Liability

Marco Rizzi

University of Seychelles; European University Institute - Law Department

Opinio Juris in Comparatione, Vol. 1/2011, Paper No. 2

The aim of this paper is to call for the need of a theoretical model of pharmaceutical products safety in which the two systems of regulation and liability operate complementarily. The question is why two legal tools that are meant to achieve and protect the same goal (protection of consumers) are shaped in a way that hinders, instead of promoting, a positive interaction between the two. At present we have two separate sets of rules that operate independently: pre-marketing regulation with post-marketing surveillance duties, and ex-post facto liability, linked to the pre-marketing available knowledge. Since the key issue in both regulatory and liability assessments related to pharmaceuticals is the one of “relevant knowledge”, we claim that the legal framework should be shaped in the way that better promotes the availability of such a knowledge. In the effort of identifying a global paradigm of pharmaceutical safety (coherent with the global nature of the relevant market), a comparison of the legal frameworks in force in the two major “regional” drug markets (US and EU) is not only necessary, but valuable in order to identify the shortcomings of “local” solutions, and their inconsistencies vis à vis the transnational nature of the issue. The fact that the two scenarios present substantial institutional differences does not hinder such a value. If we consider that the market is globalized at both the stage of production and at the one of distribution, the construction of a global governance of pharmaceutical safety has to confront with legal and institutional diversities.

Number of Pages in PDF File: 26

Keywords: pharmaceutical products, product liability, tort law, product safety, consumer safety, regulation, complementarity, regulatory compliance, preemption, harmonisation

JEL Classification: I18, K13, K23, K32, K41, L15

Open PDF in Browser Download This Paper

Date posted: June 7, 2011  

Suggested Citation

Rizzi, Marco, Regulating Risks in Pharmaceutical Law: The Need of an Optimal Interplay Between Products Safety and Products Liability. Opinio Juris in Comparatione, Vol. 1/2011, Paper No. 2. Available at SSRN: http://ssrn.com/abstract=1857434

Contact Information

Marco Rizzi (Contact Author)
University of Seychelles ( email )
Victoria - Mahe', PO B. 1348
European University Institute - Law Department ( email )
Villa Schifanoia
133 via Bocaccio
Firenze (Florence), Tuscany 50014
Feedback to SSRN

Paper statistics
Abstract Views: 539
Downloads: 97
Download Rank: 203,245
Footnotes:  127

© 2016 Social Science Electronic Publishing, Inc. All Rights Reserved.  FAQ   Terms of Use   Privacy Policy   Copyright   Contact Us
This page was processed by apollobot1 in 0.172 seconds